In silico clinical studies for optimal COVID-19 vaccination schedules in patients with cancer

Chrysovalantis Voutouri; C Corey Hardin; Vivek Naranbhai; Mohammad R Nikmaneshi; Melin J Khandekar; Justin F Gainor; Triantafyllos Stylianopoulos; Lance L Munn; Rakesh K Jain

doi:10.1016/j.xcrm.2024.101436

In silico clinical studies for optimal COVID-19 vaccination schedules in patients with cancer

Cell Rep Med. 2024 Mar 19;5(3):101436. doi: 10.1016/j.xcrm.2024.101436.

Authors

Chrysovalantis Voutouri¹, C Corey Hardin², Vivek Naranbhai³, Mohammad R Nikmaneshi⁴, Melin J Khandekar⁵, Justin F Gainor⁶, Triantafyllos Stylianopoulos⁷, Lance L Munn⁸, Rakesh K Jain⁹

Affiliations

¹ Edwin L Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; Cancer Biophysics Laboratory, Department of Mechanical and Manufacturing Engineering, University of Cyprus, Nicosia, Cyprus.
² Department of Pulmonary and Critical Care Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
³ Massachusetts General Hospital Cancer Center, Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA; Dana-Farber Cancer Institute, Boston, MA, USA; Center for the AIDS Programme of Research in South Africa, Durban, South Africa.
⁴ Edwin L Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
⁵ Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
⁶ Massachusetts General Hospital Cancer Center, Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
⁷ Cancer Biophysics Laboratory, Department of Mechanical and Manufacturing Engineering, University of Cyprus, Nicosia, Cyprus. Electronic address: tstylian@ucy.ac.cy.
⁸ Edwin L Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. Electronic address: lmunn@mgh.harvard.edu.
⁹ Edwin L Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. Electronic address: rjain@mgh.harvard.edu.

Abstract

This study introduces a tailored COVID-19 model for patients with cancer, incorporating viral variants and immune-response dynamics. The model aims to optimize vaccination strategies, contributing to personalized healthcare for vulnerable groups.

MeSH terms

COVID-19 Vaccines / therapeutic use
COVID-19* / prevention & control
Humans
Neoplasms*
Vaccination

Substances

COVID-19 Vaccines